Deliver Your News to the World

EPD Adoption Drives US Plaque Modification Market


August 11, 2005—The presence of intravessel plaque is a significant health concern for a growing portion of the US population. Over time, intravessel plaque can accumulate and harden, limiting vascular blow flow and placing an individual at an increased risk for acute myocardial infarction (heart attack), stroke, or blood clots. Though various surgical approaches exist to treat hardened plaque, physician and patient demand for preventative and less invasive treatment techniques has heightened awareness and fueled growth in the budding US plaque modification market.

According to a new report by Millennium Research Group (MRG), the US market for plaque modification, comprised of coronary atherectomy, thrombectomy, embolic protection devices (EPDs), and chronic total occlusion (CTO) devices, was valued at over $100 million in 2004 and will grow in excess of 15% through 2009. Plaque modification devices are designed for use in percutaneous coronary intervention (PCI) procedures, of which more than 1 million were performed in the US in 2004. As the US baby boomer generation ages and encounters an elevated risk for coronary artery disease, the patient population for PCI procedures will continue to increase over the foreseeable future.

With EPD penetration in PCI procedures set to quadruple by 2009, EPDs constitute the fastest-growing segment of the US plaque modification market. Physicians are increasingly adopting these devices as a stroke prevention measure. In addition to clinically based physician demand, multiple EPD product launches in 2004 and 2005, including Boston Scientific’s FilterWire EZ and Kensey Nash’s TriActiv System, will enable the EPD market to grow in excess of 40% over the next 5 years.

US Markets for Plaque Modification 2005 is part of MRG’s 2005 Marketfocus series, which offers US and European brand- and quarter-level coverage of coronary stents, PTCA balloons, and accessory devices as well as US coverage of plaque modification. MRG has also relaunched its Global Interventional Cardiology series, which features in-depth analysis of IC-related markets in the US, with forthcoming coverage of Europe, Japan, Latin America, and Asia Pacific. Global competitive coverage includes Abbott Vascular (ABT), Boston Scientific (BSX), Cordis (JNJ), Guidant (GDT), and Medtronic (MDT), among others.

A leading source of competitive intelligence, MRG is now the largest provider of medical device market research in the world. Located in Toronto, Canada, MRG covers global markets and has pioneered reporting of numerous emerging products.


This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.